Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. September 2022 09:27 ET | Quelle: Coya Therapeutics, Inc.

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)

Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been...
23. Juni 2022 09:27 ET | Quelle: Coya Therapeutics, Inc.

Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases

Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional...
15. Juni 2022 09:27 ET | Quelle: Coya Therapeutics, Inc.

Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University

Proprietary technology generates Exosome Polymer Hybrids (EPHs) which allow for efficient and versatile method of customizing cargoes of Treg-derived exosomes using oligonucleotide tethers ...
07. Juni 2022 10:02 ET | Quelle: Coya Therapeutics, Inc.

Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics

Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the immune...